Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 5/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | SLC8A1 | P32418 | 8/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4366448 | 0.87 | CSF1R (0.43) | CSF1RSLC8A1ALDH1A1ALOX5 | |
| SCHEMBL5726416 | 0.84 | THRB (0.46) | CSF1RLIPESLC8A1 | |
| SCHEMBL4953430 | 0.84 | THRB (0.46) | CSF1RLIPESLC8A1 | |
| SCHEMBL4368184 | 0.82 | HSPB1 (0.46) | CSF1RSLC8A1ALDH1A1 | |
| SCHEMBL4360457 | 0.81 | SLC8A1 (0.58) | SLC8A1 | |
| SCHEMBL4362356 | 0.81 | SLC8A1 (0.51) | SLC8A1 | |
| SCHEMBL4366645 | 0.81 | AR (0.60) | ALDH1A1CYP19A1 | |
| SCHEMBL4365832 | 0.81 | MAOB (0.60) | CYP19A1 | |
| SCHEMBL4373674 | 0.81 | SLC8A1 (0.39) | CSF1RLIPESLC8A1 | |
| SCHEMBL4372314 | 0.80 | MAPT (0.44) | CSF1RSLC8A1ALDH1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482340-B2 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2009-01-27 | — | — | US | disclosed |
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2006-10-26 | — | — | US | disclosed |
| EP-1583759-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004008837-A9 | NOVEL BENZOHYDRAZIDE DERIVATIVES AS HERBICIDES AND DESICCANT COMPOSITIONS CONTANING THEM | ISHIHARA SANGYO KAISHA (JP) | 2005-08-04 | — | — | WO | disclosed |
| WO-2004063191-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | SLC8B1, CACNA1A, MCU | CSF1R 3433/4885LIPE 3400/4885SLC8A1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.